Our Mission

To improve the lives of those suffering from the debilitating effects of degenerative diseases of the spine.

 

Our Commitment

We are revolutionizing the way millions of patients suffering from chronic back pain will be treated.

Our Focus

We are focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.

Our Approach

We are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc.

 
 

IDCT: A Regenerative Solution

DiscGenics’ first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration.

 
 
 
“We’ve seen a lot of new technologies come into the spine market in the last 25 years, but none are potentially as game changing as IDCT.”
— Matthew F. Gornet, M.D., Orthopedic Surgeon
 

JOIN THE TEAM

Grow your career in cell therapy with DiscGenics

LEARN MORE
 

Featured News

News Posts
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
The International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration
DiscGenics to Present at Canaccord Genuity 2024 Musculoskeletal Conference
DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells
DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
DiscGenics Honored by Goldman Sachs for Entrepreneurship
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
 

Disclaimer: IDCT (rebonuputemcel) is an investigational product that is under development by DiscGenics and has not been approved by the U.S. Food & Drug Administration (FDA) or any other regulatory agency for human use.